Standardized remission criteria in schizophrenia: Descriptive validity and comparability with previously used outcome measures

Pharmacopsychiatry

Volumn 41, Issue 5, 2008, Pages 190-195

  Jäger, Markus ^a   Messer, T ^b   Laux, C ^c   Pfeiffer, H ^d   Naber, D ^e   Schmidt, L G ^f   Gaebel, W ^g   Klosterkotter J ^h   Heuser, I ⁱ   Maler, W ^j   Lemke, M R ^k   Ruther E ^l   Buchkremer, C ^m   Gastpar, M ⁿ   Riedel, M ^a   Bottlender, R ^a   Strauss A ^a   Muller H J ^a  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^b District Hospital   (Germany)

^c Inn Salzach Hospital   (Germany)

^d KLINIKUM MÜNCHEN OST   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF BONN   (Germany)

^k Rheinische Kliniken   (Germany)

^l UNIVERSITY OF GÖTTINGEN   (Germany)

^m UNIVERSITY OF TÜBINGEN   (Germany)

ⁿ UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CALGARY DEPRESSION RATING SCALE FOR SCHIZOPHRENIA; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING SCORE; HAMILTON SCALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; REMISSION; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; STANDARDIZATION; VALIDITY;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 54749129890     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1078745     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM) 4th edition. Washington DC: American Psychiatric Association 1994
2. Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City: University of Iowa 1983
3. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449
4. Anghelescu IG, Kohnen R Szegedi A, Klement S, Kieser M. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry 2006; 39: 213-219
5. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measure 1960; 20: 37-46
6. Curtis CE, Calkins ME, Grove WM, Feil KJ, Iacono WG. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am J Psychiatry 2002; 158: 100-106
7. Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006; 86: 300-308
8. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 263: 743-745
9. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007; 89: 129-139
10. Guy W. Clinical Global Impressions. ECDUE Assessment Manual for psychopharmacology, revised (DHEW PUBL No. ADM 76-338) National Institute of Mental Health, Rockville, MD 1976; 218-222
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
12. Haro JM, Kamath SA, Ocheoa S, Novick D, Rele K, Fargas A et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003; 107 (suppl. 416): 16-23
13. Haro JM, Ochoa S, Gervin M, Mavreas V, Jones P. Assessment of remission in schizophrenia with the CGI and CGI-SCH scales. Acta Psychiatr Scand 2007; 115: 263-264
14. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001; 178: 506-517
15. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-482
16. Jäger M, Bottlender R, Strauss A, Möller HJ. Classification of functional psychoses and its implication for prognosis. Comparison between ICD-10 and DSM IV. Psychopathology 2004; 37: 110-117
17. Jäger M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 2007; 257: 47-53
18. Jäger M, Riedel M, Schmauß M, Laux G, Pfeiffer H, Naber D et al. Prediction of symptom remission in schizophrenia during inpatient treatment. World J Biol Psychiatry DOI: 10.1080/ 15622970701541054
19. Kay SR. Positive and negative syndromes in schizophrenia: Assessment and research. Clinical and experimental psychiatry monography No. 5. New York, NY: Brunner/Mazel 1991
20. Kujawa, Bossie CA, Lasser RA. Measuring remission in schizophrenia: response to Sethuraman et al., 2005. Schizophr Res 2006; 83: 109-110
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174
22. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005; 77: 215-227 23 Lauronen E, Koskinen J, Veijola J, Miettunen J, Jones PB, Fenton WS, Isohanni M. Recovery from schizophrenic psychoses within the Northern Finland Birth Cohort. J Clin Psychiatry 2005; 66: 375-383
23. Leucht S, Lasser RA. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006; 39: 161-170
24. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl) 2007; 194: 453-461
25. Leucht S, Davis JM, Engel RR, Kane JR, Wagenpfeil S. Defining "response" in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007; DOI:10.1038/sj.nnp.1301325
26. Liberman R, Kopelowicz, Ventura J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002; 14: 265-272
27. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L. Atypical and conventional antipsychotic drugs in treatment naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003
28. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538-546
29. Mauri MC, Volonteri LS, Dell'Osso B, Regispani F, Papa P, Baldi M, Bareggi SR. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol 2003; 23: 660-664
30. Möller HJ, Hohe-Schramm M, Cording-Tömmel C, Schmid-Bode W, Wittchen HU, Zaudig MV, Zerssen D. The classification of functional psychoses and its implications for prognosis. Br J Psychiatry 1989; 154: 467-472
31. Möller HJ. Therapieresistenz auf Antidepressiva. Definition, Häufigkeit, Prädiktoren und Interventionsmöglichkeiten. Nervenarzt 2004; 75: 499-517
32. Müller MJ, Marx-Dannigkeit P, Schlösser R, Wetzel H, Addington D, Benkert O. The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). J Psychiatr Res 1999; 33: 433-443
33. Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol 2006; 20 (6 Suppl): 57-61
34. Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004; 185: 18-24
35. Pjrek E, Winkler D, Stastny J, Praschak-Rieder N, Willeit M, Kasper S. Escitalopram in saisonal affective disorder: results of an open trial. Pharmacopsychiatry 2007; 40: 20-24
36. Sethuraman G, Taylor CC, Enerson M, Dunayevich E. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. Schizophr Res 2005; 79: 337-340
37. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 1837-1847
38. Simpson GM, Weiden P, Pigott T, Murray S, Siu CO, Romano SJ. Six month, blinded multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005; 162: 1535-1538
39. Os J van, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006; 113: 91-95
40. Os J van, Drukker M, a Campo J, Meijer J, Back M, Delespaul P. Validation of remission criteria for schizophrenia. Am J Psychiatry 2006; 163: 2000-2002
41. WHO. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. WHO, Geneva 1993 43 Wölwer W, Buchkremer G, Häfner H, Klosterkötter J, Maier W, Möller HJ, Gaebel W. German research network on schizophrenia. Bridging the gap between research and care. Eur Arch Clin Neurosci 2003; 253: 321-329
42. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2007; 33: 792-796
43. Yen CF, Chen CS, Yeh ML, Yen JY, Ker JH, Yang SJ. Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J Nerv Ment Dis 2002; 190: 847-849